Sarepeta Therapeutics shares are trading higher after the company announced FDA approval of an expansion to the labeled indication for ELEVIDYS to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. Also, multiple firms raised their respective price targets on the stock.
Portfolio Pulse from Benzinga Newsdesk
Sarepeta Therapeutics shares are trading higher following FDA approval for an expanded indication of ELEVIDYS to treat Duchenne muscular dystrophy in individuals aged 4 and older with a confirmed DMD gene mutation. Multiple firms have also raised their price targets for the stock.
June 21, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sarepeta Therapeutics shares are trading higher after FDA approval for an expanded indication of ELEVIDYS to treat Duchenne muscular dystrophy in individuals aged 4 and older with a confirmed DMD gene mutation. Multiple firms have also raised their price targets for the stock.
The FDA approval for an expanded indication of ELEVIDYS is a significant milestone for Sarepeta Therapeutics, likely leading to increased sales and revenue. Additionally, the raised price targets from multiple firms indicate strong market confidence in the stock's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100